{
  "abstract": "Dopamine replacement therapy (DRT) alleviates motor symptoms in Parkinsons disease (PD) but can trigger hallucinations in a subset of patients, yet the neural basis of this selective vulnerability is unknown. Hallucinations are among the most disabling non-motor symptoms of PD, linked to social isolation, dementia and institutionalization. Using a validated robotic paradigm to induce and quantify hallucinations in real-time, combined with resting-state fMRI in a crossover On/Off DRT design, we studied patients with PD with (PD-H) and without (PD-nH) hallucinations. DRT selectively amplified sensitivity to robot-induced hallucinations in patients with pre-existing hallucinatory phenotype (PD-H, but not PD-nH) and was accompanied by cortico-striatal and large-scale network hyperconnectivity. Rather than supporting a uniform hallucinogenic effect of dopamine in PD, these findings indicate that DRT interacts with an intrinsic neural vulnerability that varies in patients. Prospective studies will establish whether this pharmacological-behavioural signature identifies patients at risk before clinical hallucinations emerge.",
  "abstract_shown": true,
  "affiliations": [
    "EPFL"
  ],
  "article_type": "PUBLISHAHEADOFPRINT",
  "arxiv": null,
  "author_total": 11,
  "authors": [
    {
      "name": "F. Bernasconi"
    },
    {
      "name": "S. Stampacchia"
    },
    {
      "name": "L. Burget"
    },
    {
      "name": "J. Potheegadoo"
    },
    {
      "name": "M. Maradan"
    },
    {
      "name": "S. Habiby Alaoui"
    },
    {
      "name": "S. Catalano Chiuve"
    },
    {
      "name": "D. Van De Ville"
    },
    {
      "name": "P. Krack"
    },
    {
      "name": "V. Fleury"
    },
    {
      "affs": [
        0
      ],
      "name": "O. Blanke"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/b188bqsy14v8v.bib",
  "cited_by": 0,
  "doi": "10.64898/2026.09.01.26361921",
  "fulltext_url": "https://www.medrxiv.org/content/10.64898/2026.09.01.26361921v1.full",
  "id": "b188bqsy14v8v",
  "issns": [],
  "landing_url": "https://www.medrxiv.org/content/10.64898/2026.09.01.26361921v1",
  "language": null,
  "licence": "CC-BY-NC-ND",
  "licence_label": "CC BY-NC-ND",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc-nd/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "medrxiv",
      "neurology"
    ],
    [
      "openalex",
      "2728|Parkinson's Disease Mechanisms and Treatments"
    ]
  ],
  "openalex": "W7208753902",
  "pdf_url": "https://www.medrxiv.org/content/10.64898/2026.09.01.26361921v1.full.pdf",
  "pmcid": null,
  "pmid": null,
  "published": "2026-09-01",
  "publisher": null,
  "ris": "https://research.draconitic.com/paper/b188bqsy14v8v.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:17:38Z",
      "native_id": "10.64898/2026.09.01.26361921",
      "source": "medrxiv",
      "url": "https://www.medrxiv.org/content/10.64898/2026.09.01.26361921v1"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "medrxiv:neurology",
      "subfield": "neurology"
    }
  ],
  "title": "Dopaminergic therapy selectively amplifies hallucination susceptibility in patients with Parkinson's disease with cortico-striatal hyperconnectivity",
  "title_text": "Dopaminergic therapy selectively amplifies hallucination susceptibility in patients with Parkinson's disease with cortico-striatal hyperconnectivity",
  "type": "preprint",
  "updated_at": "2026-10-30T12:17:38Z",
  "url": "https://research.draconitic.com/paper/b188bqsy14v8v",
  "venue": "medRxiv",
  "versions": []
}